Insys Therapeutics Stock Price, News & Analysis (NASDAQ:INSY)

$6.20 0.17 (2.82 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$6.20
Today's Range$5.88 - $6.29
52-Week Range$4.10 - $15.02
Volume964,808 shs
Average Volume648,803 shs
Market Capitalization$454.57 million
P/E RatioN/A
Dividend YieldN/A
Beta0.81

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSY
CUSIPN/A
Phone480-500-3127

Debt

Debt-to-Equity RatioN/A
Current Ratio0.86%
Quick Ratio0.77%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$242.27 million
Price / Sales1.88
Cash Flow$0.26 per share
Price / Cash23.45
Book Value$3.76 per share
Price / Book1.65

Profitability

Trailing EPS($2.55)
Net Income$7.59 million
Net Margins-112.56%
Return on Equity-11.76%
Return on Assets-7.90%

Miscellaneous

Employees423
Outstanding Shares73,320,000

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics's stock split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were issued to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics Inc (NASDAQ:INSY) announced its quarterly earnings results on Monday, April, 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.00 by $0.03. The specialty pharmaceutical company had revenue of $54.86 million for the quarter, compared to analysts' expectations of $52.08 million. Insys Therapeutics had a negative net margin of 112.56% and a negative return on equity of 11.76%. The company's quarterly revenue was down 41.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.42 earnings per share. View Insys Therapeutics' Earnings History.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?

4 Wall Street analysts have issued 12 month price objectives for Insys Therapeutics' stock. Their predictions range from $8.00 to $11.00. On average, they anticipate Insys Therapeutics' stock price to reach $9.67 in the next year. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:

  • Steven J. Meyer, Independent Chairman of the Board (Age 60)
  • Saeed Motahari, President, Chief Executive Officer, Director (Age 51)
  • Andrew G. Long, Chief Financial Officer
  • Franc Del Fosse, General Counsel, Corporate Secretary (Age 45)
  • Rohit Vishnoi, Director
  • Pierre Lapalme, Independent Director (Age 76)
  • Brian Tambi, Independent Director (Age 71)

Who owns Insys Therapeutics stock?

Insys Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.63%), Regal Investment Advisors LLC (0.22%), Schwab Charles Investment Management Inc. (0.14%), Wells Fargo & Company MN (0.06%), GSA Capital Partners LLP (0.05%) and Janney Montgomery Scott LLC (0.02%). Company insiders that own Insys Therapeutics stock include Daniel Brennan, John N Kapoor Trust Dated Sept, Patrick Fourteau, Rohit Vishnoi, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Who sold Insys Therapeutics stock? Who is selling Insys Therapeutics stock?

Insys Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Regal Investment Advisors LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Insys Therapeutics.

Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?

Insys Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Janney Montgomery Scott LLC, Wells Fargo & Company MN and Dynamic Technology Lab Private Ltd. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of Insys Therapeutics stock can currently be purchased for approximately $6.20.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $454.57 million and generates $242.27 million in revenue each year. The specialty pharmaceutical company earns $7.59 million in net income (profit) each year or ($2.55) on an earnings per share basis. Insys Therapeutics employs 423 workers across the globe.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127.


MarketBeat Community Rating for Insys Therapeutics (INSY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insys Therapeutics (NASDAQ:INSY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.60
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.67$9.67$12.67$17.50
Price Target Upside: 87.34% upside87.34% upside26.41% upside52.44% upside

Insys Therapeutics (NASDAQ:INSY) Consensus Price Target History

Price Target History for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ:INSY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2017OppenheimerReiterated RatingHoldN/AView Rating Details
11/3/2017Jefferies GroupLower Price TargetBuy$14.00 -> $11.00N/AView Rating Details
10/27/2017Royal Bank of CanadaSet Price TargetBuy$8.00N/AView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$10.00MediumView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Insys Therapeutics (NASDAQ:INSY) Earnings History and Estimates Chart

Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ INSY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.09)$0.03$36.90 million$42.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016$0.00$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Insys Therapeutics (NASDAQ:INSY) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.63 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insys Therapeutics (NASDAQ INSY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 25.62%
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ INSY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017John N Kapoor Trust Dated SeptMajor ShareholderBuy17,500$8.93$156,275.00View SEC Filing  
8/10/2017Saeed MotahariCEOBuy5,500$8.92$49,060.00View SEC Filing  
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.00View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.00View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.00View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.00View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.00View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insys Therapeutics (NASDAQ INSY) News Headlines

Source:
DateHeadline
Insys: Turnaround Hero Of 2018? - Seeking AlphaInsys: Turnaround Hero Of 2018? - Seeking Alpha
seekingalpha.com - December 17 at 3:32 PM
 Analysts Anticipate Insys Therapeutics Inc (INSY) Will Announce Earnings of -$0.13 Per Share Analysts Anticipate Insys Therapeutics Inc (INSY) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - December 16 at 9:22 PM
INSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : December 15, 2017INSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : December 15, 2017
finance.yahoo.com - December 15 at 3:36 PM
INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : December 14, 2017INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : December 14, 2017
finance.yahoo.com - December 14 at 9:12 AM
Contrasting Insys Therapeutics (INSY) & Lipocine (LPCN)Contrasting Insys Therapeutics (INSY) & Lipocine (LPCN)
www.americanbankingnews.com - December 9 at 9:10 PM
Insys Therapeutics (INSY) Upgraded by ValuEngine to "Sell"Insys Therapeutics (INSY) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 9 at 5:08 PM
INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis - GlobeNewswire (press release)INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis - GlobeNewswire (press release)
globenewswire.com - December 7 at 10:45 AM
Insys Therapeutics (INSY) Announces FDA Drug Application for Buprenorphine Sublingual SprayInsys Therapeutics (INSY) Announces FDA Drug Application for Buprenorphine Sublingual Spray
www.streetinsider.com - December 7 at 9:10 AM
INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for AnaphylaxisINSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis
finance.yahoo.com - December 7 at 9:10 AM
Insys Therapeutics, Inc. (INSY) Given Consensus Rating of "Hold" by BrokeragesInsys Therapeutics, Inc. (INSY) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 7 at 1:46 AM
FDA Accepts New Drug Application (NDA) for Buprenorphine ... - GlobeNewswire (press release)FDA Accepts New Drug Application (NDA) for Buprenorphine ... - GlobeNewswire (press release)
globenewswire.com - December 6 at 5:42 PM
FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS TherapeuticsFDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics
finance.yahoo.com - December 6 at 11:45 AM
Companies With Very Interesting CBD TechnologyCompanies With Very Interesting CBD Technology
www.bizjournals.com - December 4 at 10:45 AM
$32.27 Million in Sales Expected for Insys Therapeutics, Inc. (INSY) This Quarter$32.27 Million in Sales Expected for Insys Therapeutics, Inc. (INSY) This Quarter
www.americanbankingnews.com - November 30 at 5:00 AM
Billionaire Insys founder can remove ankle monitorBillionaire Insys founder can remove ankle monitor
www.nasdaq.com - November 28 at 3:31 PM
Ex-Insys employee seeks to block interviews use at kickback trial - ReutersEx-Insys employee seeks to block interview's use at kickback trial - Reuters
www.reuters.com - November 28 at 9:37 AM
Billionaire Insys founder can remove ankle monitor: judge - Reuters - ReutersBillionaire Insys founder can remove ankle monitor: judge - Reuters - Reuters
www.reuters.com - November 28 at 9:37 AM
Billionaire Insys founder can remove ankle monitor -judgeBillionaire Insys founder can remove ankle monitor -judge
finance.yahoo.com - November 28 at 9:37 AM
Founder charged in opioid scheme can remove GPS monitoringFounder charged in opioid scheme can remove GPS monitoring
marketbeat.com - November 27 at 6:48 PM
Comparing Insys Therapeutics (INSY) and Neurocrine Biosciences (NBIX)Comparing Insys Therapeutics (INSY) and Neurocrine Biosciences (NBIX)
www.americanbankingnews.com - November 27 at 5:52 PM
Form 4 Insys Therapeutics, Inc. For: Nov 17 Filed by: Del Fosse FrancForm 4 Insys Therapeutics, Inc. For: Nov 17 Filed by: Del Fosse Franc
www.streetinsider.com - November 23 at 2:24 AM
Ex-Insys employees lawyer does not need disqualified from bribe case: judge - ReutersEx-Insys employee's lawyer does not need disqualified from bribe case: judge - Reuters
www.reuters.com - November 19 at 12:03 AM
Ex-Insys employees lawyer does not need disqualified from bribe case: judgeEx-Insys employee's lawyer does not need disqualified from bribe case: judge
www.reuters.com - November 18 at 7:00 PM
Insyss Kapoor ‘Tightly Controlled’ Bribe Scheme, U.S. SaysInsys's Kapoor ‘Tightly Controlled’ Bribe Scheme, U.S. Says
finance.yahoo.com - November 18 at 2:22 AM
Billionaire founder of Insys to plead not guilty to opioid bribe scheme - ReutersBillionaire founder of Insys to plead not guilty to opioid bribe scheme - Reuters
www.reuters.com - November 17 at 7:02 AM
Billionaire founder of Insys pleads not guilty to opioid bribe schemeBillionaire founder of Insys pleads not guilty to opioid bribe scheme
finance.yahoo.com - November 17 at 7:02 AM
Drug firm founder pleads not guilty to opioid bribe schemeDrug firm founder pleads not guilty to opioid bribe scheme
finance.yahoo.com - November 17 at 7:01 AM
Drug firm founder pleads not guilty to opioid conspiracyDrug firm founder pleads not guilty to opioid conspiracy
marketbeat.com - November 16 at 12:26 PM
Drug firm founder indicted in opioid conspiracy due in courtDrug firm founder indicted in opioid conspiracy due in court
marketbeat.com - November 16 at 12:22 AM
Insys founder fights electronic monitoring ahead of bribery trialInsys founder fights electronic monitoring ahead of bribery trial
www.reuters.com - November 13 at 7:58 PM
Insys Therapeutics, Inc. (INSY) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.Insys Therapeutics, Inc. (INSY) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 13 at 2:27 PM
$34.27 Million in Sales Expected for Insys Therapeutics, Inc. (INSY) This Quarter$34.27 Million in Sales Expected for Insys Therapeutics, Inc. (INSY) This Quarter
www.americanbankingnews.com - November 12 at 6:46 PM
Insys Therapeutics, Inc. (INSY) Receives Average Recommendation of "Hold" from AnalystsInsys Therapeutics, Inc. (INSY) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 12 at 1:26 AM
INSYS Therapeutics, Inc. (INSY) Expected to Announce Earnings of -$0.15 Per ShareINSYS Therapeutics, Inc. (INSY) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - November 10 at 1:16 AM
Insys Therapeutics, Inc. 2017 Q3 - Results - Earnings Call SlidesInsys Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 5 at 7:26 PM
Jefferies Group LLC Lowers Insys Therapeutics, Inc. (INSY) Price Target to $11.00Jefferies Group LLC Lowers Insys Therapeutics, Inc. (INSY) Price Target to $11.00
www.americanbankingnews.com - November 5 at 10:18 AM
Why This Marijuana Stock Didn't Sink Despite a Huge Earnings MissWhy This Marijuana Stock Didn't Sink Despite a Huge Earnings Miss
finance.yahoo.com - November 4 at 2:32 AM
Insys Therapeutics sets aside litigation fundsInsys Therapeutics sets aside litigation funds
www.marketwatch.com - November 3 at 10:16 AM
BRIEF-Insys Therapeutics reports Q3 loss per share of $2.30BRIEF-Insys Therapeutics reports Q3 loss per share of $2.30
www.reuters.com - November 3 at 10:16 AM
Form 8-K Insys Therapeutics, Inc. For: Nov 02Form 8-K Insys Therapeutics, Inc. For: Nov 02
www.streetinsider.com - November 3 at 10:16 AM
Insys Therapeutics Misses Estimates, Sets Aside Litigation FundsInsys Therapeutics Misses Estimates, Sets Aside Litigation Funds
www.wsj.com - November 3 at 10:16 AM
INSYS Therapeutics Reports Third Quarter 2017 ResultsINSYS Therapeutics Reports Third Quarter 2017 Results
finance.yahoo.com - November 3 at 10:16 AM
Insys Therapeutics posts net loss in third quarterInsys Therapeutics posts net loss in third quarter
finance.yahoo.com - November 3 at 10:16 AM
Insys Therapeutics, Inc. to Host Earnings CallInsys Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 3 at 10:16 AM
Insys Therapeutics reports 3Q lossInsys Therapeutics reports 3Q loss
finance.yahoo.com - November 3 at 10:16 AM
Insys posts bigger loss amid bribery probe of founderInsys posts bigger loss amid bribery probe of founder
finance.yahoo.com - November 3 at 10:16 AM
[$$] Insys Therapeutics Misses Estimates, Sets Aside Litigation Funds[$$] Insys Therapeutics Misses Estimates, Sets Aside Litigation Funds
finance.yahoo.com - November 3 at 10:15 AM
Edited Transcript of INSY earnings conference call or presentation 2-Nov-17 12:30pm GMTEdited Transcript of INSY earnings conference call or presentation 2-Nov-17 12:30pm GMT
finance.yahoo.com - November 3 at 10:15 AM
Insys posts loss after founder charged in U.S. opioid bribe caseInsys posts loss after founder charged in U.S. opioid bribe case
finance.yahoo.com - November 3 at 10:15 AM
ETFs with exposure to INSYS Therapeutics, Inc. : November 1, 2017ETFs with exposure to INSYS Therapeutics, Inc. : November 1, 2017
finance.yahoo.com - November 2 at 2:30 AM

SEC Filings

Insys Therapeutics (NASDAQ:INSY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insys Therapeutics (NASDAQ:INSY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insys Therapeutics (NASDAQ INSY) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.